HYPERSOLAR INCORPORATED (OTCBB: HYSR) "Up 69.09% on Monday"
HyperSolar is developing a breakthrough technology to magnify the power of the Sun to significantly increase the power output of solar cells. Based on innovative microphotonics and low cost manufacturing processes, HyperSolar is developing a thin, flat, optical layer that can inexpensively collect and deliver substantially more sunlight onto solar cells. This new approach allows solar cells to produce multiple times more power. With HyperSolar as the top layer, manufacturers can use significantly fewer solar cells in the production of solar panels, thereby dramatically reducing the cost per watt of electricity. HyperSolar technology can also be used to decouple light collection from light conversion to further reduce the cost per watt of solar panels, building integrated systems and utility scale power plants.
GLOBAL EDUCATION & TECHNOLOGY GROUP (NASDAQ: GEDU) "Up 97.39% on Monday"
Global Education & Technology Group Limited is the largest test preparation provider for IELTS and a leading provider of educational courses and related services in China. Under its "Global" brand, the Company also offers diversified services that span a student's educational life cycle, including after-school courses, overseas study consulting, and professional certification test preparation. As of June 30, 2011, the Company's network comprised 105 directly operated and 309 franchised learning centers across China, as well as an online course delivery platform with more than one million registered members.
PHARMASSET INCORPORATED (NASDAQ: VRUS) "Up 84.59% on Monday"
Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in discovering, developing, and commercializing novel drugs to treat viral infections. The company primarily focuses on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds, which act as alternative substrates for the viral polymerase, inhibiting viral replication. The company has three clinical stage product candidates, including PSI-7977, an uracil nucleotide analog polymerase inhibitor, which is initiating a Phase III clinical trials; PSI-938, a guanine nucleotide analog polymerase inhibitor that is in Phase IIb clinical trials; and RG7128, a nucleoside analog polymerase inhibitor, which is in three Phase IIb clinical trials. It has a strategic collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the development of RG7128, and PSI-6130 and its prodrugs; and a collaboration and licensing agreement with Apath, LLC. Pharmasset, Inc. was founded in 1998 and is based in Princeton, New Jersey.
OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily stock alerts go to www.otcpicks.com to sign up.
Disclosure: OTCPicks.com and affiliates has not been compensated by any of the companies covered in this release.
